Epitomap

The startup develops synthetic peptide vaccines that target zoonotic diseases by creating a pan-coronavirus vaccine that differentiates between pathogenic and non-pathogenic IgE. This approach enables the development of a personalized allergic curative drug that suppresses IgE production from B cells, addressing the need for more effective treatments for allergies and related conditions.

• Biotechnology